ZEJULA is the only once-daily oral PARP inhibitor monotherapy available for HRd patients1

Individualized starting dose gives your patients a tailored dose from the start.

View the Efficacy Data

Discover data in 1L maintenance1,2

See the Data

Once daily icon


One tablet, once daily1

Explore Dosing

Safety Profile

See safety data in 1L maintenance.1,3

Learn More


  1. ZEJULA (niraparib) Tablets. Prescribing Information. GSK; 2023.

  2. González-Martín A, Pothuri B, Vergote I, et al. N Engl J Med. 2019;381(25):2391-2402. doi:10.1056/NEJMoa1910962

  3. Mirza MR, González-Martín A, Graybill WS, et al. Cancer. 2023;129(12):1846-1855. doi:10.1002/cncr.34706